Completed PHASE3 INTERVENTIONAL 2-arm NCT01100164

A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia (Eszo)

A Phase III, Non-inferiority, Double-blind, Unicenter Clinical Trial With Two Treatment Arms - Test Group With Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

Sponsor: Eurofarma Laboratorios S.A.

Conditions INSOMNIA

Interventions Eszopiclone Zopiclone

Updated 5 times since 2017 Last updated: Jul 24, 2015 Started: Mar 31, 2011 Primary completion: Mar 31, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on INSOMNIA, this trial is completed. The trial is conducted by Eurofarma Laboratorios S.A. and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eurofarma Laboratorios S.A.

Data source: Eurofarma Laboratorios S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• São Paulo, Brazil